Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

Amany R. Keruakous, MD, Adam S. Asch, MD

Blood (2019) 134 (Supplement_1): 5864.

https://doi.org/10.1182/blood-2019-126257

Published: 2019

Journal Articles

Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials

Jessica K Roydhouse, PhD MPH, Vishal Bhatnagar, MD, Tara Berman, MD, Laurel A Menapace, MD, Rajiv Agarwal, Mallorie H. Fiero, PhD, Paul Kluetz, MD

Blood (2019) 134 (Supplement_1): 4769.

https://doi.org/10.1182/blood-2019-124168

Published: 2019

Journal Articles

The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma

Xiuli Wang, PhD, Christian Huynh, Ryan Urak, Miriam Walter, Lihong Weng, MD, Laura Lim, Vibhuti Vyas, Brenda Aguilar, Alfonso Brito, Aniee Sarkissian, Achini Bandara, PhD, Elizabeth E Budde, MD PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Christine Brown, PhD, Stephen J Forman

Blood (2018) 132 (Supplement 1): 965.

https://doi.org/10.1182/blood-2018-99-119335

Published: 2018

Journal Articles

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Vaibhav Agrawal, MD MBA, Jordyn Griffin, MD, Andrew O'Brien, MD, Robert P. Nelson, Jr., MD, Jodi L. Skiles, MD, Heiko Konig, MD PhD

Blood (2018) 132 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2018-99-114189

Published: 2018

Journal Articles

Outcome of Acute Myeloid Leukemia Patients with Abnormal 12p after Allogeneic Hematopoietic Cell Transplantation at Fred Hutchinson Cancer Research Center

Eric Konnick, MD, Yi Li, MD, Emily Silgard, MS, Chris Davis, Ted Gooley, PhD, Frederick R. Appelbaum, MD, Lue Ping Zhao, PhD, Min Fang, MDPhD

Blood (2017) 130 (Supplement 1): 1396.

https://doi.org/10.1182/blood.V130.Suppl_1.1396.1396

Published: 2017

Journal Articles

Prognostic Impact of Pregnancy on Long-Term Outcome in Acute Leukemias Patients

Vera V. Troitskaya, MD PhD, Elena N. Parovichnikova, MD PhD, Andrey N. Sokolov, MD, Alina Kokhno, MD, PhD, Zalina T. Fidarova, MDPhD, Olga A. Gavrilina, MDPhD, Anna A. Sidorova, MD, Gennadii M. Galstian, Larisa A. Kuzmina, MD PhD, Mikhail Yu. Drokov, MD PhD, Sergei Makhinya, Oleg Latishkevich, Alexandra Zvereva, Anton Olenev, Olga Korobitsyna, Alexandr Korobkin, MD, Elena Kirillova, Sergei M. Kulikov, PhD, Valery G. Savchenko, MD PhD academician

Blood (2017) 130 (Supplement 1): 4665.

https://doi.org/10.1182/blood.V130.Suppl_1.4665.4665

Published: 2017

Journal Articles

Early Paraprotein Kinetics and Response to Treatment in Multiple Myeloma

Blood (2017) 130 (Supplement 1): 4355.

https://doi.org/10.1182/blood.V130.Suppl_1.4355.4355

Published: 2017

Journal Articles

Long Term Eltrombopag in Paediatric Immune Thrombocytopenia: Update on UK Patients Treated with Eltrombopag As Part of the Petit and PETIT2 Studies

Jayne Peters, MBChB, MRCP, FRCPath, Philip P Connor, Jecko Thachil, MBBS, Indu Rakesh Thakur, FRCPath,MDMBBS, John D. Grainger, MD MRCP, FRPATH

Blood (2017) 130 (Supplement 1): 2321.

https://doi.org/10.1182/blood.V130.Suppl_1.2321.2321

Published: 2017

Journal Articles

Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States

Elizabeth K Goodman, AB, Yimei Li, PhD, Alix E. Seif, MD MPH, Julie Fitzgerald, MD PhD, Yuan-Shung Huang, MS, Rochelle Bagatell, MD, Brian T. Fisher, DO, MSCE, Richard Aplenc, MD PhD

Blood (2014) 124 (21): 553.

https://doi.org/10.1182/blood.V124.21.553.553

Published: 2014

Journal Articles

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Maxim Norkin, MD, PhD, Jan Moreb, MD, Helen Leather, BPharm, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Myron N Chang, PhD, Qi An, Ying Li, MD, PhD, Christopher R Cogle, MD, John R Wingard, MD

Blood (2013) 122 (21): 1412.

https://doi.org/10.1182/blood.V122.21.1412.1412

Published: 2013

Journal Articles

Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

Benjamin Djulbegovic, MD, PhD, Ambuj Kumar, MD, MPH, Branko Miladinovic, PhD, Asmita Mhaskar, MPH, Tea Reljic, BS, Sanja Galeb, BS, Rahul Mhaskar, MPH, PhD, Hozo Iztok, PhD, Dongsheng Tu, Heather Stanton, Christopher M Booth, Ralph M. Meyer, MD

Blood (2011) 118 (21): 508.

https://doi.org/10.1182/blood.V118.21.508.508

Published: 2011

Journal Articles

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Thoralf Lange, MD, Thomas Ernst, MD, Markus Pfirrmann, PhD, Jacqueline Maier, PhD, Martin C. Müller, MD, Franz Gruber, MD, Dietger Niederwieser, MD, Andreas Hochhaus, MD

Blood (2011) 118 (21): 1679.

https://doi.org/10.1182/blood.V118.21.1679.1679

Published: 2011

Journal Articles

Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype

Azim Mohamedali, Robert Hills, MA, MSc, DPhil, Erick E Nasser, Atiyeh Abdallah, Austin G Kulasekararaj, Amanda Gilkes, Nicholas Lea, Alan Burnett, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2010) 116 (21): 2729.

https://doi.org/10.1182/blood.V116.21.2729.2729

Published: 2010

Journal Articles

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Richard Kelly, MD, Louise Arnold, BSc, MA, Stephen J. Richards, PhD, Anita Hill, MD, Charlotte Bomken, MD, John Hanley, MD, Andrew Loughney, MD, PhD, Gus Khursigara, PhD, Russell P. Rother, PhD, Elizabeth Chalmers, MD, Edward Fitzsimons, MD, Ryotaro Nakamura, MD, Anna Gaya, MD, Bruno Rotoli, MD, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Peter Hillmen, MB, PhD

Blood (2008) 112 (11): 4576.

https://doi.org/10.1182/blood.V112.11.4576.4576

Published: 2008

Journal Articles

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine

Blood (2008) 112 (11): 4179.

https://doi.org/10.1182/blood.V112.11.4179.4179

Published: 2008

Journal Articles

Evaluation of Inherited Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia.

Valerie Li Thiao Te, MD, Remi Favier, MD, Jeanne-Yvonne Borg, MD, Estelle Cadet, MD, Jacqueline Reynaud, MD, Julie Micheli, MD, Petronela Rachieru, MD, Claire Berger, MD, Anne Auvrignon, MD, Pascale Schneider, MD, Guy Leverger, Brigitte Pautard Muchemble, MD

Blood (2007) 110 (11): 3953.

https://doi.org/10.1182/blood.V110.11.3953.3953

Published: 2007

Journal Articles

A Role for DNA Double Strand Breaks in the Sensitivity of AML Cells to Clofarabine: Enhanced In Vitro Sensitivity in Primary AML Cells with FLT3 Mutations.

Monica Pallis, PhD, Martin Grundy, BSc, Claire Seedhouse, PhD, Heather Pimblett, B Med Sci, Nigel Russell, MD

Blood (2006) 108 (11): 2582.

https://doi.org/10.1182/blood.V108.11.2582.2582

Published: 2006

Journal Articles

The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents.

Shelby D. Reed, PhD, Jasmina I. Radeva, MA, Davey Daniel, MD, John M. Fastenau, MPH, Denise Williams, MD, Kevin A. Schulman, MD

Blood (2004) 104 (11): 234.

https://doi.org/10.1182/blood.V104.11.234.234

Published: 2004

Journal Articles

Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987

M Tubiana, M Henry-Amar, P Carde, JM Burgers, M Hayat, E Van der Schueren, EM Noordijk, A Tanguy, JH Meerwaldt, J Thomas

Blood (1989) 73 (1): 47–56.

https://doi.org/10.1182/blood.V73.1.47.47

Published: 1989

NARROW

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials

The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Outcome of Acute Myeloid Leukemia Patients with Abnormal 12p after Allogeneic Hematopoietic Cell Transplantation at Fred Hutchinson Cancer Research Center

Prognostic Impact of Pregnancy on Long-Term Outcome in Acute Leukemias Patients

Early Paraprotein Kinetics and Response to Treatment in Multiple Myeloma

Long Term Eltrombopag in Paediatric Immune Thrombocytopenia: Update on UK Patients Treated with Eltrombopag As Part of the Petit and PETIT2 Studies

Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine

Evaluation of Inherited Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia.

A Role for DNA Double Strand Breaks in the Sensitivity of AML Cells to Clofarabine: Enhanced In Vitro Sensitivity in Primary AML Cells with FLT3 Mutations.

The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents.

Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only